Texas plaintiffs lawyers say some of the terms of the $3.75 billion national settlement for users of the diet-drug combination fen-phen are too lean and plan to opt out en masse.

Lawyers who object to the settlement say while the medical monitoring plan for fen-phen users who don’t show any symptoms yet is good in some ways, the compensation plan for injured class members is woefully inadequate.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]